Connect with us

Media OutReach

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results – New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Published

on

HONG KONG SAR – Media OutReach Newswire – 22 April 2025 – CK Life Sciences Int’l., (Holdings) Inc. (“the Company”) announced that the Company will be presenting new data from its cancer vaccine research pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.

The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2024 Annual Meeting attracted 23,000 in-person attendees and 6,700 online participants from 78 countries.

In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively.

PRAME is a protein highly expressed in several cancers, including melanoma, liver cancer and leukemia.

PD-L1 is one of the most important immune checkpoint proteins that is highly expressed in cancer cells to block T cell activation in the tumour microenvironment.

B7-H3 is another immune checkpoint protein that modulates T cell responses and is often overexpressed in cancer.

Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast cancer, lung cancer and endometrial cancer, where it is associated with tumour progression and metastasis.

In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines.

“CK Life Sciences is pleased with the preclinical efficacy results of its investigational cancer vaccines targeting PRAME, PD-L1, B7-H3 and Claudin 6 proteins, and we hope to further advance the research & development of these and other cancer vaccines. We are also excited about the progress achieved in our efforts to develop an AI platform aimed at designing cancer vaccines that are more likely to be immunogenic and clinically effective,” said Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences.

Dr. Toh continued, “CK Life Sciences is determined to accelerate its R&D to benefit cancer patients. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection.

DETAILS ON POSTER PRESENTATIONS:

  • Abstract 853: PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse model and induces antigen-specific immune responses

Authors: Kin-Tak Chan, Hsin-Wei Chen, Pi-Hui Liang, You-Yu Lin, Tristan Zhang, Melvin Toh

Session Category: Clinical Research
Session Title: Vaccines and Cell Therapies
Session Date and Time: 4/27/2025 2:00 PM – 5:00 PM
Location: Poster Section 35
Poster Board Number: 9

  • Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model

Authors: Na Wang, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Section 39
Poster Board Number: 9

  • Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang
Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Section 39
Poster Board Number: 12

  • Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement

Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Section 39
Poster Board Number: 14

  • Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development

Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai

Session Category: Bioinformatics/ Computational Biology/ Systems Biology/ Convergent Science
Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Section 45
Poster Board Number: 11

The full abstracts are available in the AACR Online Itinerary Planner, which can be accessed at: https://www.abstractsonline.com/pp8/#!/20273


DISCLAIMER
This press release may contain forward-looking statements regarding the Group’s research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements.
All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int’l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information.
Copyright ©2025 CK Life Sciences Int’l., (Holdings) Inc. All rights reserved.

Hashtag: #CKLifeSciences #CancerVaccines #R&D #Pharmaceutical #AmericanAssociationforCancerResearch #AACR #PRAME #PD-L1 #B7-H3 #Claudin6Proteins #Melanoma #AI

The issuer is solely responsible for the content of this announcement.

Advertisement

Media OutReach

Asia Coach Group Partners with Veteran Business Consultant Rick Tam to Launch “Business Breakthrough” Programme for Hong Kong SMEs

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – Asia Coach Group Limited announced today its partnership with seasoned business consultant Rick Tam to launch the “Business Breakthrough” enterprise training programme, designed to help Hong Kong SME owners strengthen their business models, improve cash flow, and enhance financing capabilities.

Rick Tam, Founder of “Business Breakthrough” Coaching Programme for Hong Kong SMEs

Challenging Business Environment Demands New Solutions

Hong Kong’s SMEs are facing unprecedented operational pressures. According to a survey by CPA Australia, 37% of small businesses in Hong Kong struggle to obtain external financing. Data from Airwallex further reveals that 96% of SMEs have experienced cash flow difficulties in the past year. With property asset values declining, banks’ insistence on property collateral for loans has left many enterprises in financial distress.

Responding to Market Needs with Systematic Business Upgrade Solutions

“Hong Kong has never lacked capital—what’s missing is the mechanism to connect businesses with it,” Rick Tam noted. The programme addresses common pain points faced by local SMEs, including declining profits, low business valuations, tight cash flow, and recruitment challenges. Built upon the four-pillar framework of “Commerce, Strategy, Breakthrough, and Structure,” the curriculum covers stabilising cash flow and enhancing financial flexibility, repositioning businesses and improving client quality, reshaping product value and expanding profit margins, as well as systematising operations and attracting investors. The programme commits to helping participants improve cash flow, increase business value, and strengthen their business models within 90 days.

Four Practical Tools for Immediate Application

Participants will acquire four core tools: the “Cash Flow Vortex System” for rapid assessment of financial status and establishing safety buffers; the “A.T.C. Client Leverage Ladder” for repositioning and enhancing client value; the “High-Value Breakthrough Method” for creating products with greater value and trust; and the “Marketing Triangle Matrix” for integrating human resources, client bases, and operational systems to plan business expansion. The programme adopts a six-step progressive model—from restructuring business models, improving profit margins, attracting capital injection, building high-performance teams, and systematising operations, to ultimately helping business owners reclaim their time and freedom.

Instructor Credentials

Programme instructor Rick Tam is a graduate of the University of Hong Kong’s Business School and currently serves as CEO of two family offices and chief consultant to several others. He holds the CFPCM Certified Financial Planner designation. Tam has founded more than nine brands spanning wealth management, securities, and food and beverage sectors, and has guided over 1,000 participants through business expansion.

As Hong Kong’s economy seeks transformation, channelling capital precisely into the real economy through the “Business Breakthrough” approach offers more than a lifeline for SMEs—it injects vital momentum into Hong Kong’s long-term economic development.

Hashtag: #RickTam #AsiaCoach

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer

Published

on

SINGAPORE – Media OutReach Newswire – 9 February 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.

The acquisition of the brands supports Zuellig Pharma’s strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.

“This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk® and Vapex® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands’ legacy with Zuellig Pharma’s regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers.” said John Graham, CEO of Zuellig Pharma.

Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

International Entertainment Corporation to Hold EGM on 26 February 2026 for Proposed Convertible Notes Issuance

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – International Entertainment Corporation (the “Company“, together with its subsidiaries, the “Group“; HKEX stock code: 1009) will hold an extraordinary general meeting (the “EGM”) on 26 February 2026 at 11:00 a.m. for shareholders to vote on resolutions related to the proposed issuance of up to HK$1.6 billion convertible notes (the “Notes“) to DigiPlus Interactive Corp. (the “Subscriber“) (Philippine Stock Exchange stock symbol: PLUS).

DigiPlus Interactive Corp., named as one of the Fortune Southeast Asia 500, together with its subsidiaries, is an innovative digital entertainment group in the Philippines and is a leader in the casinos and gaming industry. On 17 November 2025, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company conditionally agreed to issue and the Subscriber conditionally agreed to subscribe for the Notes in two tranches with a maturity of five years and an interest rate of 3% per annum.

Upon full conversion of the Notes at the initial Conversion Price, a total of 1,600,000,000 Shares will be issued by the Company, representing approximately 53.89% of the issued share capital of the Company as enlarged by the issue and allotment of the Conversion Shares. As such, the Subscriber will be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code, unless the Whitewash Waiver is granted and approved.

The initial Conversion Price of HK$1.00 per Conversion Share represents a discount of approximately 3.85% to the closing price of HK$1.04 per Share as quoted on the Stock Exchange on the Latest Practicable Date (6 February 2026).

The board of Directors (the “Board“) believes that the Subscription would be beneficial to improving and strengthening the Group’s liquidity and financial position on a longer-term basis. In the event that the Subscriber converts part or the full amount of the Notes into the Conversion Shares, it will also broaden the shareholder and capital base of the Company. The Group intends to apply part of the net proceeds raised from the issuance of the Notes of approximately HK$489.22 million for the early repayment of the Promissory Notes and interest accrued thereon (the “PN Repayment“), and approximately HK$392.39 million to early repay the Secured Bank Borrowing to achieve immediate interest savings.

The remaining net proceeds will primarily be used for funding the Investment Commitment and attractive investment/business opportunity(ies); and as general working capital of the Group. The Investment Commitment is currently expected to include capital investments for acquisition of land for the expansion of the Group’s integrated resort in Manila City in the Philippines (the ”Hotel”) and the construction of additional hotel rooms, for provision of other amenities of the integrated resort, and for ongoing upgrades, refurbishments and renovations to the facilities and infrastructures of both the Hotel and the Group’s existing casino (the “Casino“).

The Independent Board Committee, which comprises all the independent non-executive Directors, is of the opinion that (i) the terms of the Subscription Agreement are on normal commercial terms, and the terms of the Subscription, the Whitewash Waiver and the Special Deal (the PN Repayment to the PN Holder) are fair and reasonable so far as the Independent Shareholders are concerned; and (ii) the Subscription, the Whitewash Waiver and the Special Deal are in the interests of the Company and the Shareholders as a whole and as far as the Independent Shareholders are concerned. It, therefore, recommends the Independent Shareholders to vote in favour of the relevant resolution(s) to be proposed at the EGM.

Hashtag: #InternationalEntertainmentCorporation

The issuer is solely responsible for the content of this announcement.

About International Entertainment Corporation (HKEX: 1009)

International Entertainment Corporation is an investment holding company. The Company and its subsidiaries are principally involved in hotel operations, operating the gaming business under provisional licence and leasing of gaming venues at the hotel complex of the Group in Metro Manila in the Republic of the Philippines to a tenant for authorized gaming operation and live poker events in Macau.

Continue Reading

Trending